Goldman Sachs Exchanges Weighing the GLP-1 Market
Apr 23, 2024
Dr. Fatima Cody Stanford and Jonathan Gruber discuss the potential of GLP-1 drugs for obesity treatment, addressing their efficacy, insurance coverage issues, and implications for the US fiscal health. They explore the disparities in Medicare coverage, complexities of drug pricing, and market competition in the healthcare industry. The episode delves into setting reasonable drug prices, innovative mechanisms for negotiation, and economic impacts of expanding coverage for GLP-1 drugs.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 3min
The Role of GLP-1 Medications in Obesity Treatment
02:50 • 8min
Medicare Coverage Discrepancy for GLP-1 Medications
10:44 • 4min
Navigating Drug Pricing and Market Competition
14:31 • 6min
Exploring Drug Price Negotiation, Innovative Mechanisms, and Economic Impacts of GLP-1 Drugs
20:41 • 4min